Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity

Questions: Discounts, Updates etc.

Pages: 153

Price (Single): $3,500

Price (Departmental): $7,000

Price (Company): $10,500

Publication Date: 1-Sep-2011

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports


Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *


The report provides insights into the licensing agreements of large pharmaceutical companies. The report provides an in-depth analysis of the major licensing agreement trends in the pharmaceutical industry along with product and technology licensing trends. In addition, the report also analyzes the top 20 pharmaceutical companies with respect to the licensing agreement activities.

The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by our team of industry experts.


The scope of this report includes -

  • Major market trends that are expected to shape the licensing and deal making landscape in pharmaceutical industry
  • Trends in deals for product licensing and technology licensing agreements.
  • Extensive research and analysis of the licensing activity of large pharmaceutical companies.
  • Licensing and deal making segmentation of top 20 in the pharmaceutical companies by phase, type, geography and value
  • Company profiles of leading biotech companies active in licensing and deal making

    Reasons to buy

    The report will enhance your decision making capability. It will allow you to -
  • Develop market-entry and market expansion strategies by identifying the leading areas for licensing and deal making in the pharmaceutical industry.
  • Enable better product lifecycle management by identifying key phases of product licensing agreements.
  • Develop segment specific strategies for licensing and deal making in pharmaceutical industry.
  • Develop key strategic initiatives by understanding the key licensing and deal making focus areas of leading pharma companies.
  • Accelerate and strengthen your market position by identifying key companies for licensing agreements.
  • Table of Contents

  • 1 Table of Contents
  • 1 Table of Contents 3
  • 2 Licensing Strategies In Large Pharmaceutical Companies – Introduction 13
  • 3 Trends in In-licensing and Out-licensing Agreements 16
  • 4 Product Licensing 18
  • 5 Technology Licensing Deals 20
  • 6 Major Licensing Deals of Big Pharma Companies – 2010 21
  • 7 Licensing Strategies of Major Pharma Companies 24
  • 8 Licensing Strategies In Large Pharmaceutical Companies – Appendix 149
  • 1.1 List of Tables
  • 1.2 List of Figures
  • Other users found this report page using the following search terms: rd pharmaceutical licensing jj colicensingpharma teva licensingstrategiestrendsinthetop20pharmaceuticalcompaniesactivity licensingagreementsinthepharmaceuticalindustry strategiesonlicensingagreements outlicensingtrendsinpharma

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.

    Refund and Cancellation Policy: The descriptions of the products and services sold on are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.

    All reports are subject to copyright